Opium (Opioid) Addiction – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Opium (Opioid) Addiction – Drugs In Development, 2023’, provides an overview of the Opium (Opioid) Addiction pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction
- The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects
- The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Aether Therapeutics IncAlar Pharmaceuticals Inc
Amygdala Neurosciences Inc
Ananda Scientific Inc
Antheia Inc
Aphios Corp
AphioTx Inc
Aptinyx Inc
Aquilus Pharmaceuticals Inc
Atai Life Sciences NV
BDH Pharma LLC
Beijing Institute of Pharmacology and Toxicology
BioCorRx Inc
BioXcel Therapeutics Inc
Bridge Therapeutics Inc
Bright Minds Biosciences Inc
Camurus AB
Case Western Reserve University
Cerevel Therapeutics Holdings Inc
Ceruvia Lifesciences LLC
Cessation Therapeutics Inc
Chiesi Farmaceutici SpA
Chiromics LLC
Collaborations Pharmaceuticals Inc
Copernicus Therapeutics Inc
Creative Bio-Peptides Inc
Delpor Inc
DemeRx Inc
DMK Pharmaceuticals Corp
Eleven Therapeutics Corp
Elysium Therapeutics Inc
Ensysce Biosciences Inc
Eolas Therapeutics Inc
Epiodyne Inc
EpiVario Inc
Ethicann Pharmaceuticals USA Inc
Ethismos Research Inc
EvoDenovo Inc
Exavir Therapeutics Inc
Exxel Pharma Inc
Fab’entech SA
Fannin Partners LLC
Filament Health Corp
Gilgamesh Pharmaceuticals Inc
Hunan Saiao Pharmaceutical Co Ltd
Incannex Healthcare Ltd
Indivior Plc
Inimmune Corp
Intra-Cellular Therapies Inc
Inventage Lab Inc
Jazz Pharmaceuticals Plc
Kinoxis Therapeutics Pty Ltd
Lyndra Therapeutics Inc.
Mebias Discovery LLC
MediciNova Inc
Mount Sinai Health System
Mount Sinai Hospital
National Institute on Drug Abuse
Neurxstem Inc
New York State Psychiatric Institute
Nirsum Laboratories Inc
Nirvana Life Sciences Inc
NLS Pharmaceutics AG
Omeros Corp
Orexo AB
Osmotica Pharmaceutical Corp
Palisades Therapeutics
Paris Descartes University
Pharmnovo AB
Phoenix PharmaLabs Inc
Plumb Pharmaceuticals Inc
Proniras Corp
Revive Therapeutics Ltd
SafeRX Pharmaceuticals Inc
Sen-Jam Pharmaceutical LLC
Senzer Ltd
Serina Therapeutics Inc
Shenzhen ScienCare Pharmaceutical Co Ltd
Sparian Biosciences Inc
Syntropharma Ltd
The Scripps Research Institute
Titan Pharmaceuticals Inc
Trevena Inc
Universal Ibogaine Inc
University of Houston
University of Minnesota
VDM Biochemicals Inc
Vivozon Inc
Vivreon Biosciences LLC
Zynerba Pharmaceuticals Inc